Notably, DCLK1 has been identified as a potential RAS effector and activator in multiple studies, and DCLK1 expression in pancreatic cancer patients is correlated with RAS downstream signaling pathways ERK, PI3K, and MTOR [49,69,70,71]. This evidence concerns the gene MAPK1 and familial pancreatic carcinoma.